{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:23:12Z","timestamp":1784755392963,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    The efficacy of ciclosporin (CsA) to treat transfusion\u2010independent non\u2010severe aplastic anaemia (TI\u2010NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI\u2010NSAA treated with CsA monotherapy. CsA (3.5\u2009mg\/kg\/day) was administered to patients with TI\u2010NSAA aged \u226516. The CsA dose was adjusted to maintain a blood CsA level of \u2265600\u2009ng\/mL at 2\u2009h post\u2010administration. Blood cell counts were assessed after 8, 16 and 52\u2009weeks of therapy. Thirty\u2010two evaluable patients from 21 institutions were enrolled. The median age was 63.5 (range: 16\u201383) years. At 8\u2009weeks, haematological improvement, with increases in haemoglobin (Hb) \u22651.5\u2009g\/dL (haematological improvement in erythrocytes [HI\u2010E]) and platelet count \u226530\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L (haematological improvement in platelets [HI\u2010P]), was observed in 0\/25 (0%) and 6\/32 (19%) evaluable cases respectively. HI\u2010E and HI\u2010P occurred in 1\/25 (4%) and 10\/32 (31%) patients at 16\u2009weeks, respectively, and at 52\u2009weeks in 5\/25 (20%) and 16\/32 (50%) patients respectively. Nine grade 3 adverse events (AEs) occurred in six patients, but there were no grade \u22654 AEs. Ten of the 32 patients experienced grade 2 renal toxicity. Low\u2010dose CsA is effective in TI\u2010NSAA patients and demonstrates minimal renal toxicity. However, at least 16\u2009weeks are necessary to adequately evaluate its efficacy.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70144","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:44:08Z","timestamp":1757378648000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of ciclosporin monotherapy in non\u2010severe aplastic anaemia not requiring transfusions: Results from a multicentre phase\n                    <scp>II<\/scp>\n                    study"],"prefix":"10.1111","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-0620","authenticated-orcid":false,"given":"Ken","family":"Ishiyama","sequence":"first","affiliation":[{"name":"Department of Hematology Kanazawa University Hospital  Kanazawa Ishikawa Japan"},{"name":"Department of Hematology National Center for Global Health and Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Keiju Medical Center  Nanao Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Kanazawa University Hospital  Kanazawa Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3250","authenticated-orcid":false,"given":"Naoko","family":"Hosono","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology University of Fukui Hospital  Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Nippon Medical School  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-5460","authenticated-orcid":false,"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Okayama University Hospital  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Japanese Red Cross Fukuoka Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[{"name":"Department of Hematology NTT Medical Center Tokyo  Tokyo Japan"},{"name":"Fourth Department of Internal Medicine Mizonokuchi Hospital, Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Graduate School of Medical Science Nagoya City University  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Tumor Biology Institute for the Advanced Study of Human Biology (WPI\u2010ASHBi), Kyoto University  Kyoto Japan"},{"name":"Institute for the Advanced Study of Human Biology (WPI\u2010ASHBi) Kyoto University  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[{"name":"Sumitomo Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology Kindai University Faculty of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science Kyushu University Graduate School of Medical Sciences  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-624X","authenticated-orcid":false,"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Hematology Kanazawa University Hospital  Kanazawa Ishikawa Japan"},{"name":"Japanese Red Cross Ishikawa Blood Center  Kanazawa Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20131"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0302-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07695.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1989.tb00269.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06156"},{"key":"e_1_2_9_7_1","unstructured":"The Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.Reference guideline for the treatment of aplastic anemia [Revised edition 2022]. Available from:http:\/\/zoketsushogaihan.umin.jp\/file\/2022\/AA_final20230801.pdf"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_2_9_10_1","unstructured":"Cancer Therapy Evaluation Program NCI.Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2010. Available from:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-752378"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1741.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066217"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0465"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/518809"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10496"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009564"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01411-9"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.07052"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3706"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00008-0"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0799"},{"key":"e_1_2_9_23_1","unstructured":"Pharmaceutical and Food Safety Ministry of Health Labour and Welfare Japan.2019 Guidelines for the use of blood products."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.7.2191"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02047-z"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14210"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-005-1844-6"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414799"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109965"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19423"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70144","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:20:33Z","timestamp":1771035633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/bjh.70144"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70144","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"2025-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}